Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $13.35 and last traded at $13.44, with a volume of 9928 shares trading hands. The stock had previously closed at $13.96.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on TLX shares. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Wedbush reiterated an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. Finally, HC Wainwright began coverage on shares of Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 target price for the company.
Check Out Our Latest Stock Analysis on TLX
Telix Pharmaceuticals Trading Down 3.7%
The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The stock's 50 day moving average price is $16.12 and its 200 day moving average price is $16.91.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Private Advisor Group LLC acquired a new stake in shares of Telix Pharmaceuticals in the first quarter valued at about $170,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $297,000. Finally, ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals in the first quarter valued at approximately $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Stories
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
